• Total revenue of NZ$84.7 million (23% growth on FY24), exceeding guidance
• Normalised EBITDA profit of NZ$4.2 million (up from NZ$3.1 million loss in FY24)
• Achieved positive operating cash flow in H2 FY25

Aroa Biosurgery Limited (ASX: ARX) has released its full-year results for the period ended 31 March 2025. The company reported total revenue of NZ$84.7 million, an increase of 23% on the previous year, exceeding guidance of NZ$81-84 million. Product revenue grew 24% to NZ$84.0 million, driven by 38% growth in Myriad product revenue and 22% growth in OviTex/OviTex PRS product revenue. The company achieved a product gross margin of 86% and generated a normalised EBITDA profit of NZ$4.2 million, up from a NZ$3.1 million normalised EBITDA loss in FY24, exceeding guidance of NZ$2-4 million. Aroa also achieved positive operating cash flow in H2 FY25, with cash flows from operations of NZ$2.3 million. The company ended FY25 with a strong cash balance of NZ$22.0 million and no debt.

For FY26, Aroa expects total revenue of NZ$92-100 million (10-20% growth on FY25) and normalised EBITDA of NZ$5-8 million (19-90% growth on FY25). This guidance assumes an average NZ$/US$ exchange rate of 0.60 in FY26, no material changes to US tariff rates or medical procedure volumes, and no sustained disruption to Aroa's manufacturing or transportation activities.

Aroa is increasingly confident about its ability to deliver strong top-line growth and enhanced profitability in FY26 and beyond, driven by accelerated adoption of its Myriad product based on improved clinical outcomes, increased patient access, and reduced hospital costs.